Literature DB >> 6477859

Thermogenic drugs for the treatment of obesity: sympathetic stimulants in animal models.

A G Dulloo, D S Miller.   

Abstract

Thirty-three drugs known to stimulate the sympathetic nervous system have been screened for thermogenic properties. The results presented are for seven of them. The drugs were tested in five animal models of obesity (genetic (mice and rats), hypothalamic (mice) and dietary (mice and rats] as well as in lean mice. Energy-balance studies were undertaken using the comparative-carcass technique as well as by measurement of daily oxygen consumption. All seven drugs in obese animals tended to reduce body-weight and fat without loss of body protein: they acted by increasing metabolic rate without increasing food intake. They were much less effective in lean animals. These findings lend support to the concept that obesity is due to a diminished activity of the sympathetic nervous system. Differences in the effectiveness of the drugs are discussed in relation to differences between the animal models of obesity. Ephedrine and tranylcypromine were found to be the most effective drugs in this series of experiments and a prima facie case is made for human clinical trials.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6477859     DOI: 10.1079/bjn19840087

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  7 in total

1.  Brown adipose tissue regulates glucose homeostasis and insulin sensitivity.

Authors:  Kristin I Stanford; Roeland J W Middelbeek; Kristy L Townsend; Ding An; Eva B Nygaard; Kristen M Hitchcox; Kathleen R Markan; Kazuhiro Nakano; Michael F Hirshman; Yu-Hua Tseng; Laurie J Goodyear
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 2.  Obesity: pathophysiology and practical management.

Authors:  D L Elliot; L Goldberg; D E Girard
Journal:  J Gen Intern Med       Date:  1987 May-Jun       Impact factor: 5.128

Review 3.  The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Authors:  Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-09       Impact factor: 3.000

4.  Natural Polyphenols Inhibit Lysine-Specific Demethylase-1 in vitro.

Authors:  Arian Abdulla; Xiaoping Zhao; Fajun Yang
Journal:  J Biochem Pharmacol Res       Date:  2013-03-01

5.  Methylxanthines Inhibit Primary Amine Oxidase and Monoamine Oxidase Activities of Human Adipose Tissue.

Authors:  Wiem Haj Ahmed; Cécile Peiro; Jessica Fontaine; Barry J Ryan; Gemma K Kinsella; Jeff O'Sullivan; Jean-Louis Grolleau; Gary T M Henehan; Christian Carpéné
Journal:  Medicines (Basel)       Date:  2020-04-02

6.  The antidepressant trans-2-phenylcyclopropylamine protects mice from high-fat-diet-induced obesity.

Authors:  Adi Shemesh; Arian Abdulla; Fajun Yang; Streamson C Chua; Jeffrey E Pessin; Haihong Zong
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  The role of autonomic efferents and uncoupling protein 1 in the glucose-lowering effect of leptin therapy.

Authors:  Heather C Denroche; Michelle M Kwon; Maria M Glavas; Eva Tudurí; Marion Philippe; Whitney L Quong; Timothy J Kieffer
Journal:  Mol Metab       Date:  2016-06-24       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.